Dengue Point-of-Care Diagnostics: Progress Toward Multiplexed Rapid Testing
This review summarises progress in developing point-of-care tests for dengue, covering antigen detection, antibody-based assays, and emerging molecular platforms. A key public health need is a multiplexing assay that can differentiate dengue from Zika and other febrile illnesses with overlapping presentations. Despite numerous platform developments, independent validation and real-world implementation of dengue POCTs remain very limited, particularly in endemic regions with constrained laboratory infrastructure.
The original study
Progress and Challenges towards Point-of-Care Diagnostic Development for Dengue.
- Authors
- Pang J, Chia PY, Lye DC, Leo YS
- Journal
- Journal of clinical microbiology
- Type
- Journal Article, Review, Research Support, Non-U.S. Gov't
- PMID
- 28904181
Original abstract
Dengue detection strategies involve viral RNA, antigen, and/or antibody detection. Each strategy has its advantages and disadvantages. Optimal, user-friendly, rapid diagnostic tests based on immunochromatographic assays are pragmatic point-of-care tests (POCTs) in regions where dengue is endemic where there are limited laboratory capabilities and optimal storage conditions. Increasingly, there is a greater public health significance for a multiplexing assay that differentiates dengue from Zika or pathogens with similar clinical presentations. Although there have been many assay/platform developments toward POCTs, independent validation and implementation remain very limited. This review highlights the current key progress and challenges toward the development of a dengue POCT.